Financial Performance - The company reported a significant decline in performance for 2023, with a net profit attributable to shareholders of -605.65 million yuan, marking a substantial decrease compared to previous years[9]. - The company's operating revenue for 2023 was CNY 1,197,562,401.16, a decrease of 25.86% compared to CNY 1,615,322,934.59 in 2022[33]. - The net profit attributable to shareholders was a loss of CNY 605,653,315.00, representing a significant decline of 2,502.35% from a loss of CNY 23,273,315.49 in the previous year[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 632,325,941.80, down 727.71% from a loss of CNY 76,394,797.07 in 2022[33]. - The company's cash flow from operating activities showed a net outflow of CNY 147,425,871.69, a decrease of 123.12% compared to a net outflow of CNY 66,075,132.38 in the previous year[33]. - The company's operating profit for the reporting period was -669.71 million, a year-on-year decline of 937.70%[61]. - The company reported a significant asset impairment of -737,599,281.84, accounting for 110.95% of total profits, primarily due to goodwill and fixed asset impairments[87]. Financial Challenges - As of the end of the reporting period, the company had a net asset of 195.12 million yuan, with undistributed profits amounting to -961.75 million yuan, indicating ongoing financial challenges[8]. - The company has a funds occupation issue amounting to 179.66 million yuan, which represents 92.08% of the latest audited net assets[3]. - The company does not plan to distribute cash dividends or issue bonus shares for the fiscal year[15]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[33]. - The company has recognized asset impairment losses totaling 756 million yuan, including goodwill impairment of 439 million yuan and fixed asset impairment of 96 million yuan[9]. Market Conditions - The company is facing intense market competition in the traditional Chinese medicine sector, leading to a significant decline in revenue and gross margin[9]. - The Chinese traditional medicine market is projected to grow significantly due to an aging population, with an estimated 250 million people aged 65 and older by 2030, representing 16.9% of the population[46]. - The government has introduced multiple policies to strengthen the regulation of the traditional Chinese medicine industry, creating both opportunities and challenges for the sector[46]. - The photovoltaic industry is experiencing a high prosperity cycle, but some segments are facing overcapacity, leading to intensified market competition[48]. Strategic Initiatives - The company plans to focus on its major asset restructuring and cash acquisition of 52.7535% equity in Changjiang Star[25]. - The company aims to leverage the growing health and wellness trend among consumers, driven by rising disposable incomes and increased awareness of health maintenance[46]. - The company is actively involved in the production and sales of traditional Chinese medicine, including herbal pieces and medicinal capsules, establishing a comprehensive industry chain[44]. - The company plans to develop new business areas such as small packaging of traditional Chinese medicine, centralized decoction, and smart pharmacies to enhance its competitive edge[101]. - The company aims to strengthen its core business in traditional Chinese medicine (TCM) manufacturing, focusing on expanding the scale of TCM material planting and processing, leveraging local policy support in Hubei province[102]. Operational Efficiency - The company has implemented strict quality control measures from raw material procurement to production, ensuring compliance with GMP standards[55]. - The company has established a complete industrial chain for traditional Chinese medicine (TCM) from planting to processing and sales, enhancing its market influence and competitive advantage[62]. - The company has implemented cost reduction and efficiency improvement measures, achieving significant cost savings through centralized procurement and optimized supply chain management[63]. - The company aims to improve operational efficiency, targeting a reduction in costs by 5% through process optimization[175]. Research and Development - The company is focusing on technological innovation and process iteration in the photovoltaic sector to stimulate new production demands and accelerate equipment upgrades[49]. - The company is developing a traditional Chinese medicine formulation aimed at treating viral pneumonia and influenza, with a clinical efficacy rate of over 95%[82]. - Research and development investments have increased by 30%, focusing on advanced medical technologies[176]. - The company is actively investing in new product development, with a budget allocation of 200 million yuan for R&D in the next year, focusing on innovative therapies[199]. Governance and Compliance - The company has maintained compliance with legal and regulatory requirements, with no significant discrepancies in corporate governance practices[116]. - The company has established an independent financial accounting department and a financial management system, ensuring financial independence from the controlling shareholder[117]. - The company has implemented a performance evaluation and incentive mechanism for directors, supervisors, and senior management, promoting transparency and fairness[114]. - The company has reported a warning letter from the China Securities Regulatory Commission on September 12, 2023, regarding compliance issues[129]. Shareholder Engagement - The company held a total of four temporary shareholder meetings in 2023, with investor participation rates ranging from 15.05% to 16.16%[118]. - The company is in communication with shareholders regarding the repurchase of shares, ensuring compliance with all obligations[170]. - The company has established a commitment to avoid unnecessary related party transactions with its subsidiaries[168]. - The company is actively managing its commitments to ensure compliance with regulatory requirements and protect shareholder interests[169]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[196]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million yuan allocated for this purpose[180]. - The company aims to improve operational efficiency by implementing new technologies, which is projected to reduce costs by 15% over the next year[195]. - The company has set a target to increase its gross margin to 60% by optimizing its supply chain and production processes[196].

长江医药控股股份有限公司 关于举行2023年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"）《2023年年度报告》已于 2024年4月30日经公司第五届董事会第十五次会议审议通过，详细内容请见2024 年4月30日刊登于《证券时报》、《中国证券报》、《证券日报》、《上海证券 报》与巨潮资讯网的年报相关信息。 公司定于2024年5月16日（星期四）下午3:00-5:00，在全景网举行2023年度 网上业绩说明会。本次年度业绩说明会采用网络远程的方式举行，投资者可登陆 "全景·路演天下"（http://rs.p5w.net）参与本次年度业绩说明会。 证券代码：300391 证券简称：长药控股 公告编号：2024-025 欢迎广大投资者积极参与。 （问题征集专题页面二维码） 特此公告。 长江医药控股股份有限公司董事会 2024年4月30日 届时，公司代董事长韩庆凯先生、独立董事邓远军先生、董事副总经理兼董 事会秘书宁潞宏先生、副总经理杨月晓先生、财务总监杨英环女士将出席本次说 明会。 为充分尊重投资者 ...

Financial Performance - The company's revenue for Q1 2024 was ¥59,091,762.31, a decrease of 56.80% compared to ¥136,792,880.94 in the same period last year[5] - The net loss attributable to shareholders was ¥47,505,902.27, representing a 106.92% increase in losses from ¥22,958,141.64 year-on-year[5] - Net loss for Q1 2024 was ¥81,120,269.42, compared to a net loss of ¥30,813,220.72 in Q1 2023, representing a significant increase in losses[21] - Basic and diluted earnings per share for Q1 2024 were both -¥0.1356, compared to -¥0.0655 in the previous year[22] Cash Flow - The net cash flow from operating activities was negative at ¥32,816,721.93, a decline of 234.82% compared to a positive cash flow of ¥24,341,147.26 in the previous year[5] - Cash inflow from operating activities totaled 59,812,629.83, down 76% from 249,772,840.34 in the previous period[24] - Cash outflow from operating activities increased to 92,629,351.76, compared to 225,431,693.08 in the previous period, reflecting higher operational costs[24] - The ending cash and cash equivalents balance decreased to 2,316,745.24 from 6,054,431.45 in the previous period, indicating liquidity challenges[25] - The company received 10,250,000.00 in cash from borrowings, which was not present in the previous period, suggesting new financing efforts[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,431,968,428.54, a slight decrease of 0.40% from ¥3,445,757,061.65 at the end of the previous year[5] - Total liabilities increased to ¥2,495,767,268.42 from ¥2,428,435,632.11, indicating a rise in financial obligations[18] - The company has a total net asset of RMB 195,121,069.28, with an accumulated loss of RMB 961,745,688.98 and a net profit of RMB -605,653,315.00 for the fiscal year 2023[15] Operational Performance - The weighted average return on net assets was -27.72%, a significant drop from -2.91% in the same period last year[5] - The company’s cash flow from operating activities has been negative for two consecutive years, raising concerns about its ability to continue as a going concern[15] - The company reported a significant increase in interest expenses, totaling ¥12,788,662.59, compared to ¥9,478,334.98 in Q1 2023[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,974[10] - The largest shareholder, Changxing Shengshi Fenghua, holds 10.11% of the shares, amounting to 35,423,600 shares, with 21,002,800 shares pledged[10] Research and Development - Research and development expenses decreased by 51.33% to ¥978,777.88 from ¥2,011,134.43 year-on-year, attributed to business delays due to funding issues[8] - Research and development expenses for Q1 2024 were ¥978,777.88, a decrease of 51.4% from ¥2,011,134.43 in the same period last year[20] Fund Occupation and Risks - The company reported a significant fund occupation of RMB 179,662,019.54, accounting for 92.08% of the latest audited net assets attributable to shareholders[12] - The company is at risk of receiving additional warnings on stock trading if it fails to resolve the fund occupation issue by May 30, 2024[14] - The company plans to resolve the fund occupation issue through a debt transfer agreement, which has been approved by the board and awaits shareholder approval[14] Inventory and Receivables - Accounts receivable stood at RMB 1,603,853,809.90, slightly decreasing from RMB 1,639,156,949.32[16] - The company has a total of RMB 53,704,389.97 in inventory, which increased from RMB 51,858,189.15[16] - The company’s prepayments increased to RMB 145,416,454.20 from RMB 120,759,307.99[16]

证券代码：300391 证券简称：长药控股 公告编号：2024-011 长江医药控股股份有限公司 关于子公司重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告中铁一局集团有限公司诉被告湖北长江大药房连锁有限公司、罗明、湖 北长江伟创中药城有限公司、湖北长江星医药股份有限公司的建设工程施工合同 纠纷案于2023年8月14日进入强制执行申请阶段，湖北长江大药房连锁有限公司、 公司的子公司湖北长江丰医药有限公司和湖北长江星医药股份有限公司为被执 行人，涉案的金额109,727,911.86元。近日，公司收到中铁一局集团有限公司和 湖北长江大药房连锁有限公司、湖北长江伟创中药城有限公司、湖北长江星医药 股份有限公司签署的执行和解协议。该案涉及的1,152万元预计将对公司损益产 生影响。 一、诉讼事项受理的基本情况 2023年8月21日，长江医药控股股份有限公司（以下简称"公司"、"长药 控股"）收到中铁一局集团有限公司强制执行申请书、湖北省荆州市中级人民法 院受理案件通知书(2023)鄂10执1064号。湖北省荆州市中级人民法院所在 ...

长江医药控股股份有限公司（以下简称"公司"、"长药控股"或"上市公 司"）近日接到控股股东长兴盛世丰华商务有限公司（以下简称"盛世丰华"） 的通知，盛世丰华将其持有的公司部分股份办理了质押手续，具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质押数 | 占其所持 | 占公司 | 是否 | 是否 为补 | 质押起 | 质押 | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 总股本 | 为限 | | | 到期 | | 质权人 | | | 名称 | 大股东及其 | 量（股） | 股份比例 | | | 充质 | 始日 | | | | 用途 | | | | | | 比例 | 售股 | | | | 日 | | | | | 一致行动人 | | | | | 押 | | | | | | | | | | | | | | 2024 年 | | | 十堰市 | | | 盛世 | | | | | | | | 无固 | | 昊炜生 | 补充 | | | 是 | 4,901,100 | ...

2024年3月15日，长江医药控股股份有限公司（以下简称"公司"）收到董 事长李金凤女士提交的书面《辞呈》。因个人原因，李金凤女士辞去公司第五届 董事会董事长、董事职务，辞职后不在公司及下属公司担任任何职务。截至本公 告披露之日，李金凤女士未持有公司股票。 根据《中华人民共和国公司法》和《公司章程》的相关规定，李金凤女士的 辞职未导致公司董事会成员人数低于法定最低人数，不会影响公司董事会的规范 运作及公司正常经营，其辞职报告自送达董事会之日起生效。 公司将按照相关法律法规尽快完成董事的补选、董事长的选举。经公司董事 会半数以上董事共同推举，在董事会选举产生新任董事长前，由公司董事韩庆凯 先生代为履行董事长职责，主持董事会日常工作，直至选举产生新任董事长为止。 公司董事会对李金凤女士在任职期间为公司所做的贡献表示衷心的感谢。 特此公告。 长江医药控股股份有限公司董事会 2024年3月16日 证券代码：300391 证券简称：长药控股 公告编号：2024-009 长江医药控股股份有限公司 关于董事长辞职的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 ...

长江医药控股股份有限公司 独立董事专门会议议事规则 长江医药控股股份有限公司 独立董事专门会议议事规则 第五条 公司应当保障独立董事召开专门会议前配合独立董事提供公司运营 情况资料，组织或者配合开展实地考察等工作。公司应当为独立董事履行职责提 供必要的工作条件和人员支持，指定董事会办公室、董事会秘书等专门部门和专 1 第一章 总则 第一条 为了维护长江医药控股股份有限公司（以下简称"公司"）全体股 东的合法利益，进一步完善公司法人治理结构、提升规范运作水平，促使独立董 事更有效地履行职责和科学决策，根据《中华人民共和国证券法》《深圳证券交 易所上市公司自律监管指引第 2 号-创业板上市公司规范运作》《上市公司独立 董事管理办法》（以下简称《管理办法》）等有关法律、法规、部门规章、规范 性文件及《长江医药控股股份有限公司章程》（以下简称《公司章程》）、《独 立董事工作制度》的规定，结合公司实际情况，制定本规则。 第二章 会议的召开和通知 第二条 独立董事专门会议应当由过半数独立董事共同推举一名独立董事召 集和主持。召集人不履职或者不能履职时，两名及以上独立董事可以自行召集并 推举一名代表主持。公司应当为独立董事 ...

证券代码：300391 证券简称：长药控股 公告编号：2024-006 长江医药控股股份有限公司 关于召开2024年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2024年第一次临时股东大会 2、股东大会召集人：本次股东大会的召集人为董事会 3、会议召开的合法、合规性：公司第五届董事会第十四次会议审议通过了 《关于召开2024年第一次临时股东大会的议案》，召集程序符合有关法律、行政 法规、部门规章、规范性文件和公司《章程》的规定。 4、会议召开时间： 现场会议时间：2024年2月21日（星期三）下午14:30 网络投票时间：2024年2月21日。其中，通过深圳证券交易所交易系统进行网 络投票的时间为2024年2月21日上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2024年2月21日9:15-15:00。 5、会议召开方式：现场投票与网络投票相结合的方式。 现场投票：股东本人出席现场会议或者通过授权委托书（见附 ...

证券代码：300391 证券简称：长药控股 公告编号：2024-005 长江医药控股股份有限公司 关于修订公司章程的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（下称"公司"或"长药控股"）于2024年1月 30日召开第五届董事会第十四次会议，审议通过《关于修订<公司章程>的议案》， 现将具体事项公告如下： 1 一、修订《公司章程》的情况 根据《公司法》、《上市公司章程指引》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》等相关法律、法规及规范性文件的规定， 结合公司实际情况，公司拟修订《公司章程》部分条款，内容如下： | 原《公司章程》条款 | 修订后《公司章程》条款 | | --- | --- | | 第一条 为维护公司、股东 | 第一条 为维护长江医药控股股份有限公司（以下简称"公 | | 和债权人的合法权益，规范公 | 司"）、股东和债权人的合法权益，规范公司的组织和行为，根据 | | 司的组织和行为，根据《中华 | 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 | | 人民共和国 ...

长江医药控股股份有限公司 独立董事工作制度 长江医药控股股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善长江医药控股股份有限公司（以下简称"公司"）治 理结构，促进公司规范运作，保护广大投资者利益，根据《中华人民共和国证券 法》《深圳证券交易所上市公司自律监管指引第 2 号-创业板上市公司规范运作》 《上市公司独立董事管理办法》（以下简称《管理办法》）等有关法律、法规、 部门规章、规范性文件及《长江医药控股股份有限公司章程》（以下简称《公司 章程》）的规定，结合公司实际情况，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独立客观判断关系的董事。 独立董事对公司及全体股东负有忠实与勤勉的义务，独立董事应当按照法律、 行政法规、中国证监会规定、深圳证券交易所业务规则和《公司章程》的规定， 认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护公司 整体利益，保护中小股东合法权益。 第三条 独立董事应当独立履行职责，不受公司主要股东、实际控制人或者 与公司及其主要股东、实 ...